Table 8. Adverse effects during obinutuzumab-bendamustine therapy.

	CLL; n (% of all CLL patients)						FL; n (% of all FL patients)
	total	CTCAE Grade 1	2	3	4	5	total	CTCAE Grade 1	2	3	4	5
Infusion-related allergic reactions	1 (12,5)	0	0	1 (12,5)	0	0	0	0	0	0	0	0
Anemia	6 (75)	3 (37,5)	1 (12,5)	1 (12,5)	0	0	3 (42,9)	3 (42,9)	0	0	0	0
Thrombocytopenia	7 (87,5)	4 (50)	1 (12,5)	1 (12,5)	1 (12,5)	0	6 (85,7)	5 (71,4)	0	1 (14,3)	0	0
Leukopenia	4 (50)	3 (37,5)	1 (12,5)	0	0	0	6 (85,7)	5 (71,4)	0	1 (14,3)	0	0
Neutropenia	2 (25)	0	0	1 (12,5)	1 (12,5)	0	2 (28,6)	1 (14,3)	0	0	1 (14,3)	0
Febrile Neutropenia	2 (25)	0	0	1 (12,5)	1 (12,5)	0	0	0	0	0	0	0
Pneumonia	1 (12,5)	0	0	1 (12,5)	0	0	0	0	0	0	0	0
Bronchial Infection	1 (12,5)	0	1 (12,5)	0	0	0	0	0	0	0	0	0
Diarrhea	1 (12,5)	0	1 (12,5)	0	0	0	0	0	0	0	0	0
Sepsis	0	0	0	0	0	0	0	0	0	0	0	0
Solid tumors	0	0	0	0	0	0	0	0	0	0	0	0

Abbreviations: CTCAE: Common Terminology Criteria for Adverse Events.